Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | FADS1 | O60427 | 2/20 | 0.51 |
| ▸ | GCK | P35557 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761455 | 0.82 | FADS1 (0.55) | FADS1GCKRECQLALDH1A1 | |
| SCHEMBL589838 | 0.82 | SMN1; SMN2 (0.63) | NPC1RAB9AIDO1ALDH1A1 | |
| SCHEMBL2694674 | 0.81 | NPC1 (0.54) | NPC1RAB9AIDO1SMYD3P2RX7 | |
| SCHEMBL591754 | 0.80 | NPC1 (0.47) | NPC1RAB9AIDO1SMYD3P2RX7 | |
| SCHEMBL26099697 | 0.78 | ALDH1A1 (0.54) | NPC1RAB9AP2RX7ALDH1A1 | |
| SCHEMBL589973 | 0.78 | NPC1 (0.46) | NPC1RAB9AIDO1SMYD3P2RX7 | |
| SCHEMBL26099699 | 0.78 | ALDH1A1 (0.54) | NPC1RAB9AP2RX7ALDH1A1 | |
| SCHEMBL25391003 | 0.77 | RAB9A (0.57) | NPC1RAB9AIDO1SMYD3P2RX7 | |
| SCHEMBL22768700 | 0.77 | RAB9A (0.57) | NPC1RAB9AIDO1SMYD3P2RX7 | |
| SCHEMBL28115234 | 0.76 | NPC1 (0.44) | NPC1RAB9AIDO1SMYD3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496901-B | The manufacture method of anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| CN-103204811-B | Process for production of anthranilamide compound | ISHIHARA SANGYO KAISHA | 2015-02-04 | — | — | CN | disclosed |
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| CN-103204811-A | Process For Production Of Anthranilamide Compound | ISHIHARA SANGYO KAISHA | 2013-07-17 | — | — | CN | disclosed |
| CN-101558056-B | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA | 2013-05-01 | — | — | CN | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| CN-101558056-A | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA (JP) | 2009-10-14 | — | — | CN | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | NPC1 4477/4885RAB9A 146/4885FADS1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.